Yesterday it was reported that five young patients, who had suffered with systemic lupus erythematosus, are in remission after CAR-T-cell therapy, raising hopes that similar success might be achieved in other autoimmune diseases such as rheumatoid arthritis and multiple sclerosis theguardian.com/science/202...
The cases are written up in Nature Medicine nature.com/articles/s41591-...
According to the study, the therapy in effect wiped out the patients’ aberrant B cells and dramatically improved their condition. The disease affected multiple organs in all five patients, but after the therapy severe symptoms including arthritis, fatigue, fibrosis of the heart valves, and lung inflammation all cleared up. Blood tests on the patients showed that their B cells recovered about four months after the treatment, but they no longer produced aberrant antibodies and the patients remained disease-free.
Writing in the journal, the authors speculate that the therapy led to a “rebooting of the immune system”. “We are very excited about these results,” said Prof Georg Schett, a rheumatologist who led the work at Friedrich-Alexander University in Erlangen-Nuremberg. “Several other autoimmune diseases which are dependent on B cells and show autoantibodies may respond to this treatment. These include rheumatoid arthritis, myositis and systemic sclerosis. But also diseases like multiple sclerosis may be very responsive to CAR T-cell treatment.”
CAR-T-therapy, first used in 2015 to treat an infant with acute lymphoblastic leukaemia, has since been used with some success in other forms of leukaemia including CLL.
There are a lot of "ifs" in this, but the prospect of broader therapeutic application could attract research funds to the technology of CAR-T-cell therapy, which should drive up its efficacy-safety profile and drive down costs, perhaps making CAR-T a viable salvage therapy for a greater number of CLL patients.
CAR-T technology is already making strides biopharma-reporter.com/Arti...